University of Cincinnati and Spark Biomedical Launch Trial to Evaluate Neurostimulation Device for Opioid Use Disorder and PTSD

The University of Cincinnati, in collaboration with Spark Biomedical, is launching a groundbreaking trial aimed at evaluating a wearable neurostimulation device's effectiveness in aiding patients with opioid use disorder and post-traumatic stress disorder (PTSD) in adhering to medication treatment regimens. Spearheaded by Dr. Joel Sprunger, this research endeavor has received a substantial $2.1 million grant from the National Institute on Drug Abuse.

The trial seeks to address the critical need for innovative interventions to support individuals grappling with opioid addiction and PTSD. By leveraging state-of-the-art neurostimulation technology, researchers aim to provide new insights into how wearable devices can improve medication adherence and optimize therapeutic outcomes for these complex conditions.